Table 1.
Rates of diversion for tapentadol IR, tapentadol ER, and other Schedule II opioids, July 1, 2011 through September 30, 2014
| Tapentadol immediate release (IR) |
Tapentadol extended release (ER) |
Other Schedule II opioids |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Year-quarter | Cases | Population rate (95% CI) | Prescription rate (95% CI) | Cases | Population rate (95% CI) | Prescription rate (95% CI) | Cases | Population rate (95% CI) | Prescription rate (95% CI) |
| 2009-3 | 0 | 0(0,0.002) | 0(0,0.106) | NA | NA | NA | 2,208 | 1.459(1.399,1.522) | 0.21(0.202,0.219) |
| 2009-4 | 2 | 0.002(0,0.006) | 0.045(0.005,0.163) | NA | NA | NA | 2,010 | 1.759(1.683,1.838) | 0.205(0.196,0.214) |
| 2010-1 | 0 | 0(0,0.003) | 0(0,0.065) | NA | NA | NA | 2,138 | 1.866(1.788,1.947) | 0.218(0.209,0.227) |
| 2010-2 | 0 | 0(0,0.002) | 0(0,0.044) | NA | NA | NA | 1,918 | 1.264(1.208,1.321) | 0.171(0.164,0.179) |
| 2010-3 | 2 | 0.002(0,0.006) | 0.021(0.003,0.077) | NA | NA | NA | 2,433 | 2.116(2.032,2.201) | 0.232(0.223,0.242) |
| 2010-4 | 3 | 0.003(0.001,0.008) | 0.026(0.005,0.077) | NA | NA | NA | 2,068 | 1.896(1.816,1.98) | 0.201(0.193,0.21) |
| 2011-1 | 4 | 0.003(0.001,0.008) | 0.028(0.008,0.073) | NA | NA | NA | 1,998 | 1.645(1.574,1.719) | 0.188(0.18,0.197) |
| 2011-2 | 5 | 0.004(0.001,0.01) | 0.033(0.011,0.078) | NA | NA | NA | 2,214 | 1.86(1.783,1.939) | 0.207(0.199,0.216) |
| 2011-3 | 4 | 0.003(0.001,0.007) | 0.029(0.008,0.074) | NA | NA | NA | 2,041 | 1.454(1.391,1.518) | 0.185(0.177,0.194) |
| 2011-4 | 6 | 0.005(0.002,0.01) | 0.041(0.015,0.09) | 0 | 0(0,0.003) | 0(0,0.161) | 1,906 | 1.452(1.388,1.519) | 0.178(0.17,0.186) |
| 2012-1 | 1 | 0.001(0,0.004) | 0.007(0,0.041) | 0 | 0(0,0.003) | 0(0,0.115) | 2,259 | 1.582(1.517,1.648) | 0.207(0.199,0.216) |
| 2012-2 | 3 | 0.002(0,0.007) | 0.023(0.005,0.068) | 0 | 0(0,0.003) | 0(0,0.097) | 1,755 | 1.32(1.259,1.383) | 0.167(0.159,0.175) |
| 2012-3 | 3 | 0.003(0.001,0.009) | 0.029(0.006,0.085) | 0 | 0(0,0.004) | 0(0,0.101) | 1,681 | 1.811(1.726,1.9) | 0.188(0.179,0.197) |
| 2012-4 | 4 | 0.005(0.001,0.012) | 0.04(0.011,0.102) | 0 | 0(0,0.004) | 0(0,0.094) | 1,532 | 1.81(1.72,1.903) | 0.174(0.165,0.183) |
| 2013-1 | 3 | 0.003(0.001,0.008) | 0.031(0.006,0.089) | 1 | 0.001(0,0.005) | 0.025(0.001,0.141) | 1,866 | 1.628(1.555,1.703) | 0.203(0.194,0.212) |
| 2013-2 | 4 | 0.003(0.001,0.009) | 0.042(0.011,0.107) | 1 | 0.001(0,0.005) | 0.025(0.001,0.139) | 1,564 | 1.325(1.26,1.392) | 0.165(0.157,0.174) |
| 2013-3 | 3 | 0.003(0.001,0.01) | 0.037(0.008,0.109) | 2 | 0.002(0,0.008) | 0.056(0.007,0.202) | 1,580 | 1.732(1.647,1.819) | 0.182(0.174,0.192) |
| 2013-4 | 3 | 0.004(0.001,0.01) | 0.039(0.008,0.113) | 0 | 0(0,0.004) | 0(0,0.105) | 1,376 | 1.612(1.528,1.699) | 0.164(0.156,0.173) |
| 2014-1 | 1 | 0.001(0,0.006) | 0.013(0,0.071) | 0 | 0(0,0.004) | 0(0,0.099) | 1,384 | 1.509(1.431,1.591) | 0.165(0.156,0.174) |
| 2014-2 | 0 | 0(0,0.003) | 0(0,0.041) | 2 | 0.002(0,0.006) | 0.045(0.005,0.161) | 1,263 | 1.051(0.994,1.111) | 0.132(0.125,0.139) |
| 2014-3 | 5 | 0.006(0.002,0.014) | 0.068(0.022,0.158) | 1 | 0.001(0,0.007) | 0.026(0.001,0.144) | 1,131 | 1.332(1.256,1.412) | 0.13(0.122,0.138) |
| Total cases/Mean rates* | 56 | 0.003(0.002,0.004) | 0.03(0.021,0.042) | 7 | 0.001(0,0.001) | 0.016(0.007,0.034) | 38,325 | 1.495(1.366,1.637) | 0.172(0.158,0.187) |
*Mean rates were calculated using data from 2011-4 to 2013-4 as data for all products are available during this time. Total cases are calculated since 2009-3; NA - Not applicable, drug not available for sale at during this period.